Development and validation of novel interpretable survival prediction models based on drug exposures for severe heart failure during vulnerable period.

The survival prediction tools established in this study can be applied to severe HF patients during vulnerable period by mainly inputting drug treatment duration, thus contributing to optimal clinical decisions prospectively.